| Literature DB >> 35565226 |
Augustinas Bausys1,2,3, Morta Mazeikaite4, Klaudija Bickaite3, Bernardas Bausys3, Rimantas Bausys1,2, Kestutis Strupas1,3.
Abstract
Esophagogastric cancer is among the most common malignancies worldwide. Surgery with or without neoadjuvant therapy is the only potentially curative treatment option. Although esophagogastric resections remain associated with major surgical trauma and significant postoperative morbidity. Prehabilitation has emerged as a novel strategy to improve clinical outcomes by optimizing physical and psychological status before major surgery through exercise and nutritional and psychological interventions. Current prehabilitation programs may be unimodal, including only one intervention, or multimodal, combining the benefits of different types of interventions. However, it still is an investigational treatment option mostly limited to clinical trials. In this comprehensive review, we summarize the current evidence for the role of prehabilitation in modern esophagogastric cancer surgery. The available studies are very heterogeneous in design, type of interventions, and measured outcomes. Yet, all of them confirm at least some positive effects of prehabilitation in terms of improved physical performance, nutritional status, quality of life, or even reduced postoperative morbidity. However, the optimal interventions for prehabilitation remain unclear; thus, they cannot be standardized and widely adopted. Future studies on multimodal prehabilitation are necessary to develop optimal programs for patients with esophagogastric cancer.Entities:
Keywords: esophageal cancer; esophagectomy; exercise; gastrectomy; gastric cancer; prehabilitation
Year: 2022 PMID: 35565226 PMCID: PMC9102916 DOI: 10.3390/cancers14092096
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Figure 1Literature search flow diagram.
Characteristics of studies investigating prehabilitation for esophagogastric cancer surgery.
| Author; Year | Design | Description and Number of Participants; (n) | Measured Outcomes | N–O Score | Jadad Score |
|---|---|---|---|---|---|
| Allen et al. [ | RCT | Esophagogastric cancer patients scheduled for surgery after neoadjuvant chemotherapy; | Primary outcome: Change in AT by CPET. Change in peak VO2 by CPET; Sarcopenia measured by computed tomography; HGS; Health-related quality of life by EORTC QLQ-C30 questionnaire, Beck Anxiety Inventory, and Beck Depression score; Full adherence to the planned neoadjuvant chemotherapy and its toxicity; Weekly step count; Postoperative morbidity; 30-day hospital readmission rate; 3-year mortality rate. | N/A | 3 |
| Minnella et al. [ | RCT | Esophagogastric cancer patients scheduled for surgery ± neoadjuvant treatment; ( | Primary outcome: Change in functional capacity over time by 6MWD. Postoperative morbidity at 30 days; Length of hospital stay; 30-day hospital visits; 30-day readmission rates; 30-day death rates; Full adherence to the planned neoadjuvant chemotherapy; Compliance with prehabilitation program. | N/A | 3 |
| Valkenet et al. [ | RCT | Esophageal cancer patients scheduled for surgery ± neoadjuvant treatment; ( | Primary outcome: Postoperative pneumonia rate. Respiratory muscle function: maximum inspiratory pressure and inspiratory muscle endurance; Pulmonary function: expiratory volume in 1 s and FVC; Postoperative complication rate; Duration of mechanical bowel ventilation; Length of hospital stay; Quality of life by EuroQol-5D and SF-12 questionnaires; Physical activity by SQUASH questionnaire; Fatigue by MFI-20 questionnaire. | N/A | 3 |
| van Adrichem et al. [ | RCT | Esophageal cancer patients scheduled for surgery ± neoadjuvant CRT; ( | Primary outcome: Postoperative pulmonary complications rate. Length of stay; Stay in ICU; Number of reintubations; Maximal inspiratory pressure before and after training; Lung functions (FVC, FEV1, FEV1/FVC, and PIF); Feasibility by the number of IMT-related adverse events, compliance to training, and a self-estimated load of participation. | N/A | 3 |
| Xu et al. [ | Pilot study (RCT) | Esophageal cancer patients scheduled for neoadjuvant CRT and surgery; ( | Primary outcomes: Functional walking capacity by 6MWD and strength by HGS; Nutritional status by BW and fat-free lean mass by bioelectrical impedance. Treatment tolerance by interruptions in chemotherapy or radiotherapy; unplanned hospital admission; grade > 2 neutropenia; fever > 38.5 °C; intravenous nutritional support and wheelchair use. | N/A | 3 |
| Yamana et al. [ | RCT | Esophageal cancer patients scheduled for surgery ± neoadjuvant treatment; ( | Primary outcome: Postoperative pulmonary complication rate. Respiratory function by FVC, FEV1, FEV1%, and PEF. | N/A | 3 |
| Christensen et al. [ | Non-randomized control trial | Patients with GOJ adenocarcinoma scheduled for neoadjuvant treatment and surgery; ( | Primary outcome: Frequency of serious adverse events (defined as events that prevented surgery). Neoadjuvant treatment tolerability; Postoperative complication rate; Postoperative hospital stay; Patient-reported tolerability to neoadjuvant treatment by FACT-E questionnaire; Response to treatment by infiltration of the resection margin and immunoscore, tumor regression grade by Mandard, and pathological tumor stage (pTNM). | 8 | N/A |
| Dettling et al. [ | Non-randomized controlled trial | Patients scheduled for esophagectomy ± neoadjuvant treatment; ( | Primary outcomes: Feasibility by the occurrence of adverse effects, patients’ satisfaction; Initial effectiveness by pre-operative improvement in respiratory function. Postoperative pneumonia rate; Length of hospital stay; Duration of mechanical ventilation; Reintubation rate; Length of stay in the ICU; Postoperative morbidity rate. | 8 | N/A |
| Argudo et al. [ | Pilot study (prospective interventional study) | Esophagogastric cancer patients scheduled for neoadjuvant treatment and surgery; ( |
Feasibility by TELOS components; Tolerability; Exercise capacity by cardiopulmonary exercise testing; Pulmonary and muscle function; Peripheral muscle function; Health-related quality of life by EORTC QLQ-C30 questionnaire. | 6 | N/A |
| Piraux et al. [ | Pilot study (prospective interventional study) | Esophagogastric cancer | Primary outcome Feasibility (recruitment, retention and attendance rates, adverse events, and patient satisfaction). Functional exercise capacity by 6MWD; CRF by FACIT-F scale; Quality of life by FACT-G questionnaire; Anxiety and depression by HADS questionnaire. | 6 | N/A |
| Yamamoto et al. [ | Pilot study (prospective interventional study) | Gastric cancer patients |
Nutritional intake (total number of calories and protein daily intake); Body composition (body mass, fat mass, lean body mass); Sarcopenia parameters (handgrip strength, gait speed, and skeletal muscle mass index). | 6 | N/A |
| Cho et al. [ | Matched pair analysis | Patients with clinical stage I gastric cancer and metabolic syndrome scheduled for gastrectomy; | Primary outcome: Postoperative complications rate. The operative time; Intraoperative blood loss; Hospital stay; Visceral fat and body weight. | 7 | N/A |
RCT: randomized controlled trial; CRT: chemoradiotherapy; N/A: not applicable; GOJ: gastroesophageal junction; AT: anaerobic threshold; CPET: cardiopulmonary exercise testing; 6MWD: six minute walking distance; HGS: hand-grip strength; BW: body weight; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; FEV1%: forced expiratory volume in the first second predicted; PEF: peak expiratory flow.
Structure of interventions in prehabilitation programs for esophagogastric cancer surgery.
| Author; Year | Prehabilitation Group | Control Group | ||
|---|---|---|---|---|
| Type of Prehabilitation (Unimodal vs. Multimodal) | Timing of Prehabilitation | Interventions Used for Prehabilitation | ||
| Allen et al. [ | Multimodal | Prehabilitation was initiated for 15 preoperative weeks. |
Exercise intervention: supervised aerobic, resistance, and flexibility training twice a week and home-based exercise training three times per week; Nutritional intervention: needs-based nutritional interventions with frequent, tailored dietetic input from specialist dieticians, increasing calorie and protein intake where appropriate depending on assessments and physical activity levels; Psychological intervention: six sessions of medical coaching, which included discussion of health status, strength recognition, resilience profiling and development, social and support systems, emotional management, and goal setting. |
Standard of care |
| Minnella et al. [ | Multimodal | Prehabilitation was initiated before the initial surgery or at the time of neoadjuvant therapy. |
Exercise intervention: individualized, home-based exercise training program including aerobic and strengthening exercise; Nutritional intervention: metabolic requirement was adjusted to meet the increased nutritional demand. Food-based dietary advice was given, and a whey protein supplement was prescribed to guarantee a daily protein intake. |
Standard of care |
| Valkenet et al. [ | Unimodal | Prehabilitation was initiated for 2 weeks or longer. When neoadjuvant therapy was administered, prehabilitation started afterward. |
Exercise intervention: inspiratory muscle training. |
Standard of care |
| van Adrichem et al. [ | Unimodal | Prehabilitation was initiated for 3 weeks. When neoadjuvant therapy was administered, prehabilitation started afterward. |
Exercise intervention: high-intensity inspiratory muscle training. |
Exercise intervention: endurance inspiratory muscle training |
| Xu et al. [ | Multimodal | Prehabilitation was initiated for 4–5 weeks during the neoadjuvant chemoradiotherapy. |
Exercise intervention: nurse-supervised walking; Nutritional intervention: nutritional advice. |
Standard of care |
| Yamana et al. [ | Unimodal | Prehabilitation was initiated for ≥7 days before the surgery. |
Exercise intervention: respiratory muscle training; muscle strengthening exercises for the lower limbs and abdominal muscles; biking on an ergometer. |
Standard of care |
| Christensen et al. [ | Unimodal | Prehabilitation was initiated at the time of neoadjuvant treatment. |
Exercise intervention: supervised high-intensity aerobic and resistance exercise. |
Standard of care |
| Dettling et al. [ | Unimodal | Prehabilitation was initiated for 2 weeks or longer. |
Exercise intervention: inspiratory muscle training. |
Standard of care |
| Argudo et al. [ | Multimodal | Prehabilitation was initiated after neoadjuvant chemotherapy for 5 weeks. |
Exercise intervention: high-intensity interval training on the ergometric bicycle; respiratory muscle training using a respiratory muscle trainer. Nutritional intervention: individualized nutritional therapy based on nutritional status and ability to fulfill caloric-protein requirements. |
N/A |
| Piraux et al. [ | Unimodal | Prehabilitation was initiated for 2–4 weeks before the surgery. |
Exercise intervention: aerobic, resistance, and respiratory muscle training using an online tele-prehabilitation platform. |
N/A |
| Yamamoto et al. [ | Multimodal | Prehabilitation was initiated for 3 weeks, although the actual duration differed depending on the surgery date. |
Exercise intervention: handgrip training, walking, and resistance training; Nutritional intervention: nutritional advice and 2.4 g daily oral supplementation with leucine metabolite b-hydroxy-b-methylbutyrate (HMB). |
N/A |
| Cho et al. [ | Unimodal | Prehabilitation was initiated for 4 weeks. |
Exercise intervention: aerobic exercise, resistance training, and stretching. |
Standard of care |
CRT: chemoradiotherapy; N/A: not applicable.
Outcomes of included studies evaluating prehabilitation for esophagogastric cancer surgery.
| Author; Year | Prehabilitation Impact on Physical Status | Prehabilitation Impact on Postoperative Outcomes | Other Effects of Prehabilitation |
|---|---|---|---|
| Allen et al. [ | Prehabilitation attenuated peak VO2 decrease and skeletal muscle loss following neoadjuvant therapy. Additionally, HGS was better retained in the prehabilitation group, and patients in this group were more physically active by higher weekly step count. | Prehabilitation had no impact on the | Prehabilitation improved QoL by global health status after 2 cycles of neoadjuvant chemotherapy and at 2 weeks, 6 weeks, and 6 months postoperatively. Additionally, prehabilitation resulted in better BAI and DBI II scores preoperatively and 6 weeks and 6 months postoperatively. |
| Minnella et al. [ | Prehabilitation improved functional capacity before and after surgery by increasing 6MWD. | Prehabilitation had no impact on the number and severity of complications, length of hospital stay, emergency department visits, and readmission rates. | N/A |
| Valkenet et al. [ | Prehabilitation resulted in a higher increase in inspiratory muscle strength and endurance. | Prehabilitation did not affect postoperative pneumonia and other postoperative complication rates. | Prehabilitation did not affect the quality of life, fatigue, and physical activity levels. |
| van Adrichem et al. [ | The increase in maximal inspiratory pressure was similar between the groups which received preoperative inspiratory muscle training. | The incidence of postoperative pulmonary complications, length of stay, and the number of reintubations were lower in the high-intensity inspiratory muscle training group. | N/A |
| Xu et al. [ | Prehabilitation ameliorated decline in 6MWD and hand-grip strength. | N/A | Prehabilitation ameliorated weight and lean muscle mass loss. |
| Yamana et al. [ | Prehabilitation did not affect respiratory function representing parameters (FVC, FEV1, FEV1%, and PEF). | Prehabilitation ameliorated the severity of postoperative complications (by lower Clavien–Dindo score) and postoperative pneumonia (by lower Utrecht Pneumonia Scoring System score). | N/A |
| Christensen et al. [ | Prehabilitation resulted in improved fitness and muscle strength. | Prehabilitation did not affect the postoperative complication rate. | Prehabilitation resulted in improved quality of life by FACT-E score. |
| Dettling et al. [ | Prehabilitation increased inspiratory muscle strength and endurance. | Prehabilitation did not affect postoperative pneumonia and other complication rates. | N/A |
| Argudo et al. [ | Prehabilitation improved exercise capacity in terms of VO2 peak and workload and distance improvement in the 6MWD and inspiratory and expiratory muscle strength. | N/A | Prehabilitation resulted in the improvement of some domains of health-related quality of life (social and role functions). |
| Piraux et al. [ | N/A | N/A | Prehabilitation improved fatigue, quality of life, physical well-being, emotional well-being, and anxiety. |
| Yamamoto et al. [ | Prehabilitation significantly increased handgrip strength. | N/A | Prehabilitation improved nutritional uptake by increasing calorie and protein intake. |
| Cho et al. [ | N/A | Prehabilitation decreased hospital stay and the number of severe postoperative complications (anastomotic leakage, pancreatic fistula, intra-abdominal abscess, and other severe abdominal complications). | Prehabilitation significantly decreased BMI, bodyweight, abdominal circumference, and visceral fat. |
6MWD: six minute walking distance; N/A: not applicable; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; FEV1%: forced expiratory volume in the first second predicted; PEF: peak expiratory flow.